Case-Based Roundtable Meetings Spotlight: March 2, 2023
Roundtable Discussion: Carraway Assesses Remaining Challenges in BPDCN Patient Population
April 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hetty E. Carraway, MD, MBA, discussed with participants diagnosing and treating patients with BPDCN, as well as the remaining challenges in this space.
Roundtable Discussion: Krishnan Debates the Rationale For Various Therapies in Multiple Myeloma
March 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Amrita Krishnan, MD, discussed with participants their choice of therapy for a patient with multiple myeloma who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant and 2 years of lenalidomide maintenance.
Dosing and Management: Optimal Use of Tafasitamab/Lenalidomide for Relapsed DLBCL
March 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bruce D. Cheson, MD, discussed adverse event management and dosing strategies for patients receiving tafasitamab and lenalidomide for diffuse large B-cell lymphoma.
Oh Explores Current JAK Inhibitor Options for Primary Myelofibrosis
March 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen Oh, MD, discussed treatment options for steroid-refractory high-risk primary myelofibrosis based on the patient's platelet count.
Clinical Commentary: Addressing Treatment Tactics in Blastic Plasmacytoid Dendritic Cell Neoplasms
March 20th 2023Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.
Ajani Discusses Immune Checkpoint Inhibition in HER2-Negative Upper GI Cancer
March 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.
Dosing and Toxicity: Managing Adverse Events of Single-Agent ICIs in Endometrial Cancer
March 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bhavana Pothuri, MD, MS, discussed with participants their experiences managing adverse events of immunotherapy for advanced endometrial cancer.
Burns Compares Therapies Approved for NSCLC With an EGFR Exon 20 Insertion Mutation
March 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the trials supporting the use of mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
